Gewinn- und Verlustrechnung von Illumina, Inc.

Illumina builds on strong NovaSeq X demand and clinical sequencing momentum, but China weakness and cost pressures keep challenges in focus.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Swiss pharma and diagnostics giant Roche on Monday launched its ​long-awaited Axelios gene sequencer, in a bid to challenge ‌U.S. firm Illumina's leadership in next-generation sequencing.

Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026.

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights.